<?xml version="1.0" encoding="UTF-8"?>
<p id="Par102">We and others have described CD133
 <sup>+</sup> cells as an immature population of endothelial progenitors highly overlapping with CD34
 <sup>+</sup> cells and having enhanced paracrine-driven proangiogenic effects [
 <xref ref-type="bibr" rid="CR16">16</xref>, 
 <xref ref-type="bibr" rid="CR34">34</xref>â€“
 <xref ref-type="bibr" rid="CR36">36</xref>]. In 2015, we were the first to report the full-GMP compliant validation of BM-derived human CD133
 <sup>+</sup> cells to be used as an ATMP for cardiac CT [
 <xref ref-type="bibr" rid="CR17">17</xref>] in compliance with the European Medicine Agency (EMA) guidelines [
 <xref ref-type="bibr" rid="CR37">37</xref>] and the Committee of Advance Therapies (CAT) recommendations [
 <xref ref-type="bibr" rid="CR38">38</xref>].
</p>
